Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 7/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2579588 | 1.00 | ACE (0.56) | ACEFOLH1NAALAD2MMEACE2 | |
| SCHEMBL8823272 | 0.87 | ACE (0.58) | ACEFOLH1NAALAD2MMEACE2 | |
| SCHEMBL953389 | 0.87 | FOLH1 (0.56) | ACEFOLH1NAALAD2MMEACE2 | |
| SCHEMBL8823270 | 0.87 | ACE (0.58) | ACEFOLH1NAALAD2MMEACE2 | |
| SCHEMBL838885 | 0.87 | FOLH1 (0.56) | ACEFOLH1NAALAD2MMEACE2 | |
| SCHEMBL27802669 | 0.85 | ACE (0.53) | ACEFOLH1NAALAD2MMEACE2 | |
| SCHEMBL17393507 | 0.84 | ACE (0.56) | ACEFOLH1NAALAD2MMEACE2 | |
| SCHEMBL7136038 | 0.79 | FOLH1 (0.51) | ACEFOLH1NAALAD2MMEACE2 | |
| SCHEMBL1008925 | 0.78 | FOLH1 (0.56) | ACEFOLH1NAALAD2MMEACE2 | |
| SCHEMBL160418 | 0.78 | FOLH1 (0.60) | ACEFOLH1NAALAD2MMEACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230284994-A1 | PET-CT IMAGING METHODS, CONTRAST AGENTS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN SAID IMAGING METHODS | Adiposs SA (CH) | 2023-09-14 | — | — | US | disclosed |
| EP-4192521-A1 | PET-CT IMAGING METHODS, CONTRAST AGENTS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN SAID IMAGING METHODS | Adiposs SA (CH) | 2023-06-14 | — | — | EP | disclosed |
| US-20220153790-A1 | HIGH AFFINITY ANTICALINS DIRECTED AGAINST HUMAN CD98hc | Technische Universität München (DE) | 2022-05-19 | — | — | US | disclosed |
| EP-3947453-A1 | HIGH AFFINITY ANTICALINS DIRECTED AGAINST HUMAN CD98HC | Technische Universität München (DE) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020193316-A1 | HIGH AFFINITY ANTICALINS DIRECTED AGAINST HUMAN CD98HC | Technische Universität München (DE) | 2020-10-01 | — | — | WO | disclosed |
| EP-3715370-A1 | HIGH AFFINITY ANTICALINS DIRECTED AGAINST HUMAN CD98HC | Technische Universität München (DE) | 2020-09-30 | — | — | EP | disclosed |
| US-20100249416-A1 | CHEMICAL SYNTHESIS OF I-124BETA CIT IODINE-124 [2-BETA-CARBOMETHOXY-3BETA- (4. -IODOPHENYL) -TROPANE] FOR PET INVESTIGATIONS AND FOR RADIOTHERAPY | A.C.O.M ADVANCED CENTER ONCOLOGY MACERATA S.P.A. (IT) | 2010-09-30 | — | — | US | disclosed |
| EP-2212320-A1 | CHEMICAL SYNTHESIS OF I-124BETA CIT IODINE-124 [2-BETA-CARBOMETHOXY-3BETA- (4. -IODOPHENYL) -TROPANE] FOR PET INVESTIGATIONS AND FOR RADIOTHERAPY | A.C.O.M. Advanced Center Oncology Macerata S.p.a. (IT) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009141137-A2 | NEW MOLECULE [124I][2-(3'-IODO-4'-METHYLAMINOPHENYL)-6-HYDROXY-BENZOTHIALZOLE] FOR PET INVESTIGATIONS AND RADIOTHERAPY | SPARKLE S.R.L. (IT) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009046897-A1 | CHEMICAL SYNTHESIS OF I-124BETA CIT IODINE-124 [2-BETA-CARBOMETHOXY-3BETA- (4. -IODOPHENYL) -TROPANE] FOR PET INVESTIGATIONS AND FOR RADIOTHERAPY | A.C.O.M ADVANCED CENTER ONCOLOGY MACERATA S.P.A. (IT) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230284994-A1 | PET-CT IMAGING METHODS, CONTRAST AGENTS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN SAID IMAGING METHODS | FABP4, PLIN5, PLIN3 | ACE 3206/4885FOLH1 199/4885NAALAD2 3780/4885 |
| US-20100249416-A1 | CHEMICAL SYNTHESIS OF I-124BETA CIT IODINE-124 [2-BETA-CARBOMETHOXY-3BETA- (4. -IODOPHENYL) -TROPANE] FOR PET INVESTIGATIONS AND FOR RADIOTHERAPY | INMT, THRB, TPO | ACE 2096/4885FOLH1 758/4885NAALAD2 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.